Epigenetic mechanisms play important roles in the maladaptive transcriptional and behavioral responses to drugs of abuse. Inhibition of bromodomain and extra‐terminal domain (BET) proteins, a class of histone acetylation reader proteins, has been shown to reduce cocaine‐seeking behaviors in animal models of addiction. To date, the role of BET protein in animal models of substance use disorder (SUD) has only been evaluated using pan‐BET inhibitors, small molecules that bind to both bromodomains (BD1 and BD2) in all BET proteins. Although these initial studies are encouraging, side effects associated with pan‐BET inhibitors may limit their clinical utility as a SUD treatment. In order to evaluate safer and more selective approaches, we utilized a clinically tested BD2 selective BET inhibitor, RVX‐208. We show that RVX‐208 dose‐dependently reduced cocaine conditioned place preference in male mice, similar to the pan‐BET inhibitor JQ1. Additionally, RVX‐208 did not alter other behaviors, such as: locomotor activity, elevated zero maze, or novel object recognition memory. At the transcriptional level, RVX‐208 attenuated the expression of multiple cocaine‐induced genes in the nucleus accumbens. RVX‐208 also produced a distinct transcriptional response in stimulated primary neurons compared to JQ1 but had little effect on gene expression in non‐stimulated neurons. Together, these data indicate that targeting domain‐specific BET mechanisms may be an effective and safer strategy to reduce cocaine‐induced neurobehavioral adaptations.